224 related articles for article (PubMed ID: 34514094)
1. Oncolytic herpes virus G47Δ works synergistically with CTLA-4 inhibition via dynamic intratumoral immune modulation.
Sugawara K; Iwai M; Ito H; Tanaka M; Seto Y; Todo T
Mol Ther Oncolytics; 2021 Sep; 22():129-142. PubMed ID: 34514094
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Enhances the Antitumor Efficacy of Radiofrequency Ablation.
Yamada T; Tateishi R; Iwai M; Koike K; Todo T
Mol Ther Oncolytics; 2020 Sep; 18():535-545. PubMed ID: 32995479
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.
Ju F; Luo Y; Lin C; Jia X; Xu Z; Tian R; Lin Y; Zhao M; Chang Y; Huang X; Li S; Ren W; Qin Y; Yu M; Jia J; Han J; Luo W; Zhang J; Fu G; Ye X; Huang C; Xia N
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688558
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic augmentation of oncolytic virus therapy for central nervous system malignancies.
Shimizu K; Kahramanian A; Jabbar MADA; Turna Demir F; Gokyer D; Uthamacumaran A; Rajan A; Saad MA; Gorham J; Wakimoto H; Martuza RL; Rabkin SD; Hasan T; Wakimoto H
Cancer Lett; 2023 Sep; 572():216363. PubMed ID: 37619813
[TBL] [Abstract][Full Text] [Related]
6. Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors.
Yamada T; Tateishi R; Iwai M; Tanaka M; Ijichi H; Sano M; Koike K; Todo T
Mol Ther Oncolytics; 2023 Mar; 28():31-43. PubMed ID: 36619294
[TBL] [Abstract][Full Text] [Related]
7. Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor.
Kagabu M; Yoshino N; Murakami K; Kawamura H; Sasaki Y; Muraki Y; Baba T
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768352
[TBL] [Abstract][Full Text] [Related]
8. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells.
Farrell CJ; Zaupa C; Barnard Z; Maley J; Martuza RL; Rabkin SD; Curry WT
Clin Cancer Res; 2008 Dec; 14(23):7711-6. PubMed ID: 19047097
[TBL] [Abstract][Full Text] [Related]
9. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
Saha D; Martuza RL; Rabkin SD
Cancer Cell; 2017 Aug; 32(2):253-267.e5. PubMed ID: 28810147
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis.
Uchihashi T; Nakahara H; Fukuhara H; Iwai M; Ito H; Sugauchi A; Tanaka M; Kogo M; Todo T
Mol Ther Oncolytics; 2021 Sep; 22():388-398. PubMed ID: 34553027
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a third-generation oncolytic herpes virus G47Δ in models of human esophageal carcinoma.
Yajima S; Sugawara K; Iwai M; Tanaka M; Seto Y; Todo T
Mol Ther Oncolytics; 2021 Dec; 23():402-411. PubMed ID: 34853811
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a Third-Generation Oncolytic Herpes Virus G47Δ in Advanced Stage Models of Human Gastric Cancer.
Sugawara K; Iwai M; Yajima S; Tanaka M; Yanagihara K; Seto Y; Todo T
Mol Ther Oncolytics; 2020 Jun; 17():205-215. PubMed ID: 32346610
[TBL] [Abstract][Full Text] [Related]
13. Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1.
Zhu Y; Hu X; Feng L; Yang Z; Zhou L; Duan X; Cheng S; Zhang W; Liu B; Zhang K
Mol Ther Oncolytics; 2019 Dec; 15():201-213. PubMed ID: 31788554
[TBL] [Abstract][Full Text] [Related]
14. Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47delta.
Wang J; Xu L; Zeng W; Hu P; Zeng M; Rabkin SD; Liu R
Cancer Cell Int; 2014; 14(1):83. PubMed ID: 25360068
[TBL] [Abstract][Full Text] [Related]
15. Treatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus.
Wang JN; Xu LH; Zeng WG; Hu P; Rabkin SD; Liu RR
Asian Pac J Cancer Prev; 2015; 16(3):1241-5. PubMed ID: 25735362
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
Fukuhara H; Martuza RL; Rabkin SD; Ito Y; Todo T
Clin Cancer Res; 2005 Nov; 11(21):7886-90. PubMed ID: 16278413
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis.
Ghouse SM; Nguyen HM; Bommareddy PK; Guz-Montgomery K; Saha D
Front Oncol; 2020; 10():384. PubMed ID: 32266155
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant use of oncolytic herpes virus G47Δ prevents local recurrence after insufficient resection in tongue cancer models.
Inoue K; Ito H; Iwai M; Tanaka M; Mori Y; Todo T
Mol Ther Oncolytics; 2023 Sep; 30():72-85. PubMed ID: 37583387
[TBL] [Abstract][Full Text] [Related]
20. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
Wang J; Hu P; Zeng M; Rabkin SD; Liu R
Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
